SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending due to concerns about increased spending on AI and infrastructure, despite strong revenue growth and a one-time tax charge impacting EPS. The community is debating whether the sell-off is an overreaction and a buying opportunity, or a sign of weakening profitability and a shift in investor sentiment. Some traders are anticipating a bounce back to the 50-day moving average, while others see further downside potential.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

UAMY is trending due to renewed discussions around antimony supply and potential impacts from trade relations, particularly regarding export controls from China and a recently rejected acquisition offer. Community members are weighing the implications of these factors on the company's future, discussing the possibility of a short squeeze, and the potential for government support to bolster domestic antimony production.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet's stock is trending as strong AI demand and advertising growth drove its Q3 revenue above expectations, prompting increased capital expenditure forecasts and community excitement. Investors are reacting positively to Alphabet's favored cash flow strategy and AI investments, while some analysts are predicting further gains. Community members are actively discussing the stock's potential to reach new price levels and its long-term investment value.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle's stock is trending due to concerns about slowing growth and reduced guidance, sparking debate about its valuation and future prospects. Community discussions center on whether the brand is losing its value proposition amid rising prices and inconsistent portions, with some criticizing the CEO's handling of the situation. Investors are weighing whether the dip presents a buying opportunity or signals deeper issues within the company and the broader consumer discretionary sector.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

VKTX is trending as traders discuss potential catalysts from upcoming conferences and strong revenue growth in the obesity sector from competitors. The community speculates about buyout possibilities, comparing VKTX's assets and market cap to recent acquisitions in the space. Bullish sentiment remains high due to positive clinical data and analysts' price targets.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending amid mixed reactions to its earnings, with analysts debating the impact of AI spending on future growth; despite strong cloud performance, some express concerns about increased capital expenditures. Community discussions revolve around whether the company's valuation remains justified in light of its AI investments and competition in the cloud sector, with some speculating on a potential post-earnings dip.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Roblox ($RBLX) is trending amid discussions around its Q3 earnings report, which showed higher revenue and lower EPS than expected, alongside FY25 bookings guidance. The community is actively debating the company's valuation and future prospects, while some express concerns related to broader market conditions and commentary around the platform's content.

Alphabet Inc - Ordinary Shares - Class C

GOOG is trending amid positive sentiment driven by AI advancements and anticipation of strong earnings, with the community discussing potential for the stock to reach new highs. Upgrades from analysts and excitement around cloud and AI revenue are fueling optimism, although some traders are wary of a potential pullback after recent gains. Additionally, a new partnership between Google and NextEra Energy to restart a nuclear plant in Iowa is generating some buzz.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending due to strong Q3 earnings, driven by high demand for weight loss drugs Mounjaro and Zepbound, which beat revenue expectations and raised the FY25 guidance. The community is focused on the impact of this GLP-1 momentum, potential FDA approvals, and the company's strategic partnerships in AI, viewing LLY as a leader in the pharmaceutical sector.

ARB IOT Group Ltd. is a holding company that engages in the provision of solutions for the integration of IoT systems and devices. It operates through the Internet of Things and Investment Holding and Others segments. The company was founded on March 1, 2022 and is headquartered in Singapore.

ARB IOT Group Ltd

ARBB is trending due to significant after-hours momentum, with community members highlighting its low float and potential for a short squeeze, reminiscent of other recent runners. Traders are actively discussing entry points, price targets, and potential overnight holds, while also pointing to contracts of nearly $100 million. Despite the excitement, some caution against chasing the pump, noting the stock's volatile history.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Neumora said that NMRA-215 demonstrated weight loss of up to 19% as a monotherapy and 26% in combination with semaglutide.</li><li>The company now plans to initiate an early-stage clinical study for the experimental drug in the first quarter of 2026. &nbsp;</li></ul>Neumora Therapeutics, Inc. (NMRA) on Monday announced positive data from preclinical studies for its experimental weight-loss therapy NMRA-215.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/27/3174401/0/en/Neumora-Therapeutics-Announces-Class-Leading-Weight-Loss-Demonstrated-with-NMRA-215-in-Preclinical-Diet-Induced-Obesity-Model.html">said</a> that NMRA-215 demonstrated weight loss of up to 19% as a monotherapy and 26% in combination with Semaglutide in mice with diet-induced obesity. Semaglutide is the active ingredient in Novo Nordisk’s (NVO) popular weight-loss drug Wegovy.<h2 class="st-heading-2">Plans Ahead</h2>NMRA-215 is an oral NLRP3 inhibitor in development for the treatment of obesity. It blocks the activity of the NLRP3 inflammasome, a protein complex involved in the immune response to inflammation. NLRP3-mediated neuroinflammation in the hypothalamus is linked to obesity, Neumora noted.The company now plans to initiate an early-stage clinical study for the experimental drug in the first quarter of 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Shares of the company jumped about 22% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NMRA">NMRA stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<blockquote>“These data demonstrate NMRA-215 drives meaningful weight loss as a monotherapy in mice, including incretin-like induction, additive weight loss in the combination setting with semaglutide, as well as the potential to enable incretin-sparing dosing regimens.” – Paul Berns, CEO, Neumora Therapeutics</blockquote>Separately, Neumora on Monday also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/27/3174424/0/en/Neumora-Therapeutics-Announces-Initiation-of-Phase-1-Clinical-Study-of-M4-Positive-Allosteric-Modulator-NMRA-898.html">announced</a> the initiation of an early-stage study of its NMRA-898 aimed at evaluating safety, tolerability, and human pharmacokinetic data of the compound for potential use in the treatment of schizophrenia and other neuropsychiatric disorders.&nbsp;NMRA stock is down by 75% this year and by about 78% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/eth-outperforms-btc-as-retail-sentiment-improves-ahead-of-fed-rate-decision/cLG030ZR3Mh">Ethereum Outperforms Bitcoin As Retail Sentiment Improves Ahead Of Fed Rate Decision, Trump-Xi Meeting This Week</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Neumora Therapeutics’ Experimental Drug Demonstrates Weight Loss in Preclinical Studies

Neumora said that NMRA-215 demonstrated weight loss of up to 19% as a monotherapy and 26% in combination with Semaglutide.

Equity

Should Schwab U.S. Small-Cap ETF (SCHA) Be on Your Investing Radar?

Shares of Alto Neuroscience (ANRO) soared 54% on Friday afternoon after the company announced that the U.S. Food and Drug Administration granted Fast Track designation to ALTO-101 for the treatment of cognitive impairment associated with schizophrenia.Cognitive impairment is a core and disabling feature of Schizophrenia, a serious, disabling mental illness affecting thought, perception, and behavior. According to Alto, there are currently no approved treatments for cognitive impairment associated with schizophrenia.FDA’s Fast Track designation is designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need. A company, whose drug has a Fast Track designation, may be eligible for more frequent meetings with the FDA to discuss the drug’s development plan, as well as for accelerated approval and priority review, subject to the fulfillment of relevant criteria.ALTO-101 is an inhibitor of the PDE4 enzyme that plays a key role in the brain by breaking down a molecule fundamental to learning and memory. By inhibiting the enzyme, the drug seeks to increase the levels of the molecule believed to improve cognitive function.Alto CEO Amit Etkin <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.altoneuroscience.com/news/news-details/2025/Alto-Neuroscience-Receives-FDA-Fast-Track-Designation-for-ALTO-101-for-the-Treatment-of-Cognitive-Impairment-Associated-with-Schizophrenia/default.aspx">termed</a> the designation a significant milestone. “Our Phase 1 data, which demonstrated significant and clinically relevant effects of ALTO-101 on both EEG measures and cognitive performance in healthy subjects, provides strong validation for its mechanism,” he added.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ANRO">ANRO stock</a> rose from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:579/59;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_03_at_12_01_14_PM_png_f2a3fffa4a.webp" alt="ANRO's Sentiment Meter and Message Volume as of 12 p.m. ET on Oct. 03, 2025 | Source: Stocktwits" width="579" height="59"><figcaption>ANRO's Sentiment Meter and Message Volume as of 12 p.m. ET on Oct. 03, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user highlighted the company’s strong pipeline. Alto is seeking to develop treatments for mental health conditions, including bipolar depression, major depressive disorder, treatment-resistant depression (TRD), and schizophrenia.<stembedurl>https://stocktwits.com/Ccperk/message/630959482</stembedurl>Another user believes the FDA's Fast Track designation is the icing on the cake.<stembedurl>https://stocktwits.com/Ccperk/message/630949029</stembedurl>ANRO stock is up by 61% this year but down by 33% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rivian-reportedly-eyes-door-redesign-to-alleviate-safety-concerns-report/chCuVXzR3QQ">Rivian Reportedly Eyes Door Redesign To Alleviate Safety Concerns: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Alto Neuroscience logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Alto Neuroscience Stock Soars After FDA Grants Fast Track Designation To Schizophrenia Drug

FDA’s Fast Track designation is designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need.

ETFs to Ride the Small-Cap Comeback Wave 

Rate cut hopes and investor rotation beyond tech are fueling renewed momentum in small-cap stocks, with the Russell 2000 surging in August.

Are Small-Cap ETFs Finally Ready to Shine?

IWM is gaining momentum as rate-cut hopes, attractive valuations and rising small-business optimism fuel renewed interest in small-cap ETFs.


Shares of uniQure N.V. (QURE) were in the spotlight on Friday morning after its first quarter (Q1) revenue fell 81% year-on-year (YoY) while losses narrowed.The gene therapy company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/05/09/3078125/0/en/uniQure-Announces-First-Quarter-2025-Financial-Results-and-Highlights-of-Recent-Company-Progress.html">reported</a> revenue for the three months ended March of $1.6 million, compared to $8.5 million in the same period of 2024, and below an analyst estimate of $6.71 million, as per Finchat data.The company attributed the revenue fall to a decrease of $4 million in contract manufacturing of HEMGENIX gene therapy for biotherapeutics company CSL Behring, among other factors.uniQure, however, narrowed its quarterly loss to $0.82 per share, compared to a loss of $1.36 in the corresponding period of 2024. Analysts were estimating a loss of $1.06 per share.The narrowing of the net loss in the quarter was driven by a significant reduction in the company’s operating expenses, as it slashed employee-related expenses, facility expenses, and costs related to preclinical supplies.The firm ended the quarter with cash, cash equivalents, and current investment securities of approximately $409 million, expected to fund its operations into the second half of 2027.The company is now seeking U.S. FDA approval for its AMT-130 gene therapy as a treatment for Huntington’s disease.CEO Matt Kapusta said that the company expects to provide a regulatory update on AMT-130 in the second quarter, including guidance on the potential timing for its application to the FDA seeking approval to distribute the therapy.On Stocktwits, retail sentiment around uniQure remained unmoved within the ‘neutral’ territory over the past 24 hours while message volume remained at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:630/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_09_at_8_08_00_AM_png_281dbf2952.webp" alt="QURE's Sentiment Meter and Message Volume as of 8:08 a.m. ET on May 9, 2025 | Source: Stocktwits" width="630" height="63"><figcaption>QURE's Sentiment Meter and Message Volume as of 8:08 a.m. ET on May 9, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/QURE/sentiment">QURE stock</a> declined by 32% this year but is up by about 142% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/astrazeneca-reports-positive-data-from-cancer-drug-trial/chiWpd3RblJ">AstraZeneca Reports Positive Data From Cancer Drug Trial: Retail Sentiment Brightens</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

UniQure Narrows Q1 Loss But Revenue Plummets: Retail’s In Wait-And-Watch Mode

The company narrowed its first-quarter loss to $0.82 per share, down from $1.36 per share in 2024. 

Goldman Sachs resumes coverage on European Internet & Media, sees 22% upside

Investing.com -- Goldman Sachs has resumed coverage on 24 European Internet and Media stocks, estimating an average upside of 22% across the sector.

Shares of clinical-stage biotech firm Sangamo Therapeutics Inc. fell nearly 3% in Monday's after-hours trading following disappointing quarterly earnings, but retail investors held their bullish ground.Sangamo reported a fourth-quarter adjusted loss per share of $0.11, narrowing significantly from a loss of $0.34 a year earlier. However, this was worse than Wall Street's expected $0.09 per share loss.Revenue of $7.6 million also fell short of the consensus estimate of $11.7 million.&nbsp;CEO Sandy Macrae emphasized the company's progress over the past year, notably securing FDA approval for clinical trials of ST-503, a potential treatment for idiopathic small fiber neuropathy (iSFN)."We believe our neurology pipeline represents important potential value. In addition, we continue to engage in Fabry business development negotiations, in an effort to capitalize the business for the future," he said.Macrae added that 2025 will be a pivotal year, with plans to begin patient enrollment and dosing for the iSFN clinical study by midyear.&nbsp;The company also aims to submit a Biologics License Application (BLA) for its Fabry disease program in the second half of the year.On Stocktwits, sentiment for Sangamo ended Monday on an 'extremely bullish' note, with message volume exploding by 1200% from a day earlier.<figure class="image"><img style="aspect-ratio:1316/302;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SGMO_sentiment_and_message_volume_as_of_March_17_png_2c103aadf6.webp" alt="SGMO sentiment and message volume as of March 17.png" width="1316" height="302"><figcaption>SGMO sentiment and message volume as of March 17. | source: Stocktwits</figcaption></figure>Several optimistic users expressed confidence in Macrae's remarks about securing a third potential agreement with a major pharmaceutical company for its adeno-associated virus (AAV) capsid, STAC-BBB. The technology is designed to enhance the delivery of intravenously administered genomic medicines for specific neurological conditions.Sangamo has already licensed STAC-BBB to Roche's Genentech and Astellas Pharma.<stembedurl>https://stocktwits.com/BurkeTheBizarre15/message/608344985</stembedurl><stembedurl>https://stocktwits.com/Who_is_JohnnyGalt/message/608344869</stembedurl>Sangamo has been under pressure since December, when Pfizer ended a hemophilia drug development partnership, citing slow patient uptake for such therapies.Shares of the company have shed only about 1% this year but are up 20% over the past 12 months.According to Koyfin, five out of eight analysts covering the stock rate it 'buy' or 'strong buy', while the rest recommend 'hold'.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Sangamo Therapeutics Retail Traders Keep The Faith Even As Stock Slides After-Hours On Q4 Miss

Several optimistic users expressed confidence in the company securing a third potential agreement with a major pharma for its adeno-associated virus (AAV) capsid, STAC-BBB.

Affirm Holdings (AFRM) stock gained 13.3% in premarket trade on Friday after the company reported a surprise quarterly profit and its revenue topped Wall Street estimates.The firm reported a net income of $80.36 million, or $0.23 per share, for the fiscal second quarter, compared with a loss of $166.90 million, or $0.54 per share, in the year-ago quarter.&nbsp;Analysts were expecting a loss of $0.17 per share, according to Koyfin data.The buy now, pay later firm’s revenue jumped 46.6% to $866.4 million, exceeding the Street estimate of $807.6 million.The company said its gross merchandising volume (GMV), which implies the total value of all the transactions processed by Affirm, jumped 35% to $10.1 billion.Affirm attributed the rise to strong performance in the general merchandise and consumer electronics categories due to the strong holiday shopping season.Its active consumers rose 23% to 21 million, and its active merchant count grew 21% to 337,000.The company said its direct-to-consumer GMV rose 43% to $2.8 billion, with active Affirm cardholder count rising about 20% quarter over quarter.However, its allowances for credit losses rose to 5.4% from 5% in the year-ago quarter.Affirm forecast fiscal 2025 revenue between $3.13 and $3.19 billion and GMV between $34.74 and $35.34 billion.According to TheFly, following Thursday's earnings report, several brokerages raised the price target for the stock.Wells Fargo raised its price target on the stock to $85 from $70. The brokerage said that while no particular key performance indicator outshined the rest, a broad-based strength would help drive the company’s earnings performance better than any other firm in its coverage.Retail sentiment on Stocktwits moved higher in the ‘extremely bullish’ (92/100) territory than a day ago, while retail chatter remained ‘extremely high.’<figure class="image"><img style="aspect-ratio:799/177;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/AFRM_Feb_7_ae0eafab22.JPG" alt="AFRM’s Sentiment Meter and Message Volume as of 07:58 a.m. ET on Feb. 7, 2025 | Source: Stocktwits" width="799" height="177"><figcaption>AFRM’s Sentiment Meter and Message Volume as of 07:58 a.m. ET on Feb. 7, 2025 | Source: Stocktwits</figcaption></figure>One retail trader said that companies such as Affirm have emerged as the alternative for financial credit for many.<stembedurl>https://stocktwits.com/agente360/message/603286370</stembedurl>Over the past year, <a href="https://stocktwits.com/symbol/AFRM">Affirm stock</a> has gained 38.4%.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/honeywells-3-way-split-draws-mixed-response-from-wall-street/chPzN2eRss">Honeywell’s 3-Way Split Draws Mixed Response From Wall Street: Retail Exudes Confidence</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Affirm Holdings, Inc. logo appears on a smartphone screen in this illustration photo in Reno, United States, on December 24, 2024. (Photo by Jaque Silva/NurPhoto via Getty Images)

Affirms Holdings Stock Surges Premarket After Surprise Profit, Upbeat Q2 Revenue: Retail’s Extremely Bullish

The buy now, pay later firm’s revenue jumped 46.6% to $866.4 million, exceeding the Street estimate of $807.6 million.

Schwab Strategic Trust - Schwab U.S. Small-Cap ETF

Will Apple (AAPL) beat quarterly earnings? 
 
*Powered by Polymarket

SCHA
Schwab Strategic Trust - Schwab U.S. Small-Cap ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest SCHA News

SCHASchwab Strategic Trust - Schwab U.S. Small-Cap ETF